LifeVantage (Nasdaq:LFVN) has announced a strategic acquisition of LoveBiome, a direct sales company specializing in microbiome health solutions. The acquisition strengthens LifeVantage's position in the rapidly growing gut health market, which is projected to expand from $14.4 billion in 2025 to $32.4 billion by 2035.
The deal centers around LoveBiome's P84 product, which focuses on gut health regulation and restoration through Activation technology, complementing LifeVantage's existing portfolio including Protandim® and MindBody GLP-1 System™. The transaction is expected to close by mid-October 2025 and will be accretive to Adjusted EPS and EBITDA in the first year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.